WeTrials
Completed

Does the Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

What is this study?

This study looks at whether a medication called semaglutide can help reduce alcohol intake in people who also struggle with obesity. It aims to see if this treatment, combined with counseling, can help lower the number of heavy drinking days.

Who can participate?

You might be able to join if you are between 18 and 70 years old, have an alcohol use disorder, and have a body mass index (BMI) of 30 or higher. Certain conditions, like severe mental health issues or poorly managed diabetes, mean you cannot take part.

What will happen?

Over 26 weeks, participants will receive either weekly injections of semaglutide or a placebo, which is an inactive substance that looks like the real medicine. Everyone will also receive standard counseling, and some participants may have brain scans at the beginning and end of the study.

Where and when?

The study takes place in Frederiksberg, Denmark, and the status of this trial is currently completed.

Key Points
  • 1Tests the medication semaglutide for reducing heavy drinking days.
  • 2Combines weekly injections with standard talk therapy and counseling.
  • 3Involves adults aged 18 to 70 with both alcohol use disorder and obesity.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Alcohol AbuseAlcohol AddictionAlcohol DependenceAlcohol Use Disorder

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.